Join this EASL Studio episode for a clinical perspective on advancing HCC care. Explore the realities of adjuvant therapies, emerging molecular targets, and strategies for curative conversion. Gain insights into practical innovations shaping the future and translating research into improved patient outcomes.

Moderator: Thomas Berg
Faculty: Tim Greten and Anna Saborowski

This EASL Studio is supported by Bayer.
EASL has received no input from Bayer with regards to the content of this programme.

Related episodes

All EASL Studio Podcasts are available on EASL Campus.

Click here to see all EASL Video Podcasts on Apple Podcasts.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör European Association for the Study of the Liver. Innehållet i podden är skapat av European Association for the Study of the Liver och inte av, eller tillsammans med, Poddtoppen.

EASL Podcasts

EASL Studio Podcast: Liver Cancer Care in 2025: Progress, Hope, and What Lies Ahead

00:00